DPP-4 inhibitors × glycemic control

TrialDiabetes, obesity & metabolism2021

A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin.

Yutaka Seino et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 141 people · 2021

Randomised comparison

Probably lowered glycemic control

−0.83percentage points−1.05 to −0.62

As reported

difference −0.83 %, 95% CI −1.05 to −0.62

One number in the abstract

the abstract, start to end

(least squares [LS] mean difference -0.83% [95% confidence interval

← favours treatmentfavours comparator →
could be chance
Glycemic control
−0.83−1.05 to −0.62
DPP-4 inhibitorsGlycemic control

DPP-4 inhibitors × glycemic controlhelps?replicated

unlikelylikely
0.820.82 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

3 papers cite it

2021
2022
2023
2024
2025
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 33565686